Human criptin growth factor

Abstract

A human Criptin Growth Factor polypeptide (CGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat and/or prevent neoplasia such as tumors is also disclosed. Diagnostic assays for identifying mutations in CGF nucleic acid sequences and altered levels of the CGF for the detection of cancer are also disclosed.

What is claimed is:  
     
         1 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 a. a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 223 as set forth in SEQ ID NO:2;    b. a polynucleotide encoding the polypeptide comprising amino acid 24 to amino acid 223 as set forth in SEQ ID NO:2;    c. a polynucleotide encoding the polypeptide comprising amino acid 24 to amino acid 173 as set forth in SEQ ID NO:2;    d. a polynucleotide encoding the polypeptide comprising amino acid 24 to amino acid 128 as set forth in SEQ ID NO:2;    e. a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a), (b), (c) or (d); and    f. a polynucleotide fragment of the polynucleotide of (a), (b), (c) or (d).    
     
     
         2 . The polynucleotide of  claim 1  wherein the polynucleotide is DNA.  
     
     
         3 . An isolated polynucleotide comprising a member selected from the group consisting of: 
 a. a polynucleotide which encodes a mature polypeptide encoded by the DNA contained in ATCC Deposit No. 97142;    b. a polynucleotide which encodes a polypeptide expressed by the DNA contained in ATCC Deposit No. 97142;    c. a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a) or (b); and    d. a polynucleotide fragment of the polynucleotide of (a), (b) or (c).    
     
     
         4 . The polynucleotide of  claim 2  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 1 to nucleotide 672.  
     
     
         5 . The polynucleotide of  claim 2  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 62 to nucleotide 672 .  
     
     
         6 . The polynucleotide of  claim 2  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 69 to nucleotide 672.  
     
     
         7 . The polynucleotide of  claim 2  comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 201 to nucleotide 672.  
     
     
         8 . A vector containing the DNA of  claim 2 .  
     
     
         9 . A host cell genetically engineered with the vector of  claim 8 .  
     
     
         10 . A process for producing a polypeptide comprising: expressing from the host cell of  claim 9  the polypeptide encoded by said DNA.  
     
     
         11 . A process for producing cells capable of expressing polypeptide comprising genetically engineering cells with the vector of  claim 8 .  
     
     
         12 . A polypeptide comprising a member selected from the group consisting of (i) a polypeptide having the amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 97142 and fragments, analogs and derivatives of said polypeptide.  
     
     
         13 . A compound which activates a receptor for the polypeptide of  claim 12 .  
     
     
         14 . A compound which inhibits the polypeptide of  claim 12 .  
     
     
         15 . An antibody against the polypeptide of  claim 12 .  
     
     
         16 . A process for identifying compounds which inhibit activation of the polypeptide of  claim 12  comprising: 
 contacting cells which express a CGF receptor on the surface thereof with labeled CGP and a compound to be screened under conditions suitable for binding of ligands to said receptor; and  
 determining the extent of binding of labeled CGF to the receptor by measuring the amount of label attached to the receptor.  
 
     
     
         17 . A process for identifying compounds which inhibit activation of the polypeptide of  claim 12  comprising: 
 contacting cells which express a CGF receptor on the surface thereof with a compound to be screened under conditions suitable for binding of ligands to said receptor; and  
 determining the extent of binding of the compound to the receptor and the lack of a signal generated by the binding.  
 
     
     
         18 . A process for identifying compounds which activate a receptor to the polypeptide of  claim 12  comprising: 
 contacting cells which express a CGF receptor on the surface thereof with a compound to be screened under conditions suitable for binding of ligands to said receptor; and  
 determining the extent of binding of the compound to the receptor and the presence of a signal generated by the binding.  
 
     
     
         19 . A process for diagnosing a disease or a susceptibility to a disease related to a mutation in the polynucleotide of  claim 1  comprising: 
 determining a mutation in the polynucleotide of  claim 1 .  
 
     
     
         20 . A diagnostic process comprising: 
 analyzing for the presence of the polypeptide of  claim 12  in a sample derived from a host.